000275477 001__ 275477
000275477 005__ 20240229154942.0
000275477 0247_ $$2doi$$a10.1186/s13058-023-01625-4
000275477 0247_ $$2pmid$$apmid:37069615
000275477 0247_ $$2pmc$$apmc:PMC10108482
000275477 0247_ $$2ISSN$$a1465-5411
000275477 0247_ $$2ISSN$$a1465-542X
000275477 0247_ $$2altmetric$$aaltmetric:146077081
000275477 037__ $$aDKFZ-2023-00784
000275477 041__ $$aEnglish
000275477 082__ $$a610
000275477 1001_ $$0P:(DE-He78)2d4cac0f4bf270325b98fe07036dc6c6$$aLe Cornet, Charlotte$$b0$$eFirst author$$udkfz
000275477 245__ $$aPostdiagnosis circulating osteoprotegerin and TRAIL concentrations and survival and recurrence after a breast cancer diagnosis: results from the MARIE patient cohort.
000275477 260__ $$aLondon$$bBioMed Central$$c2023
000275477 3367_ $$2DRIVER$$aarticle
000275477 3367_ $$2DataCite$$aOutput Types/Journal article
000275477 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1681981233_32562
000275477 3367_ $$2BibTeX$$aARTICLE
000275477 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000275477 3367_ $$00$$2EndNote$$aJournal Article
000275477 500__ $$a#EA:C020#LA:C020#
000275477 520__ $$aExperimental studies suggest a role for osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in mammary tumor development and progression. These biomarkers have been minimally investigated with respect to outcomes in breast cancer patients.OPG and TRAIL were evaluated in blood samples collected from 2459 breast cancer patients enrolled in the MARIE study, a prospective population-based patient cohort, at median of 129 days after diagnosis. Participants were between ages 50 and 74 at diagnosis and recruited from 2002 to 2005 in two regions of Germany. Follow-up for recurrence and mortality was conducted through June 2015. Delayed-entry Cox proportional hazards regression was used to assess associations between OPG and TRAIL with all-cause and breast cancer-specific mortality, and recurrence, both overall and by tumor hormone receptor status.Median follow-up time was 11.7 years, with 485 deaths reported (277 breast cancer-specific). Higher OPG concentrations were associated with a higher risk of all-cause mortality (hazard ratio for 1-unit log2-transformed concentration (HRlog2) = 1.24 (95% confidence interval 1.03-1.49). Associations were observed in women diagnosed with ER-PR- tumors or discordant hormone receptor status (ER-PR-, HRlog2 = 1.93 (1.20-3.10); discordant ERPR, 1.70 (1.03-2.81)), but not for women with ER + PR + tumors (HRlog2 = 1.06 (0.83-1.35)). OPG was associated with a higher risk of recurrence among women with ER-PR- disease (HRlog2 = 2.18 (1.39-3.40)). We observed no associations between OPG and breast cancer-specific survival, or for TRAIL and any outcome.Higher circulating OPG may be a biomarker of a higher risk of poor outcome among women diagnosed with ER- breast cancer. Further mechanistic studies are warranted.
000275477 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000275477 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000275477 650_7 $$2Other$$aBreast cancer survival
000275477 650_7 $$2Other$$aEstrogen receptor status
000275477 650_7 $$2Other$$aOPG
000275477 650_7 $$2Other$$aTRAIL
000275477 650_7 $$2NLM Chemicals$$aOsteoprotegerin
000275477 650_7 $$2NLM Chemicals$$aLigands
000275477 650_7 $$2NLM Chemicals$$aTNF-Related Apoptosis-Inducing Ligand
000275477 650_7 $$2NLM Chemicals$$aTumor Necrosis Factor-alpha
000275477 650_7 $$2NLM Chemicals$$aBiomarkers
000275477 650_7 $$2NLM Chemicals$$aHormones
000275477 650_2 $$2MeSH$$aHumans
000275477 650_2 $$2MeSH$$aFemale
000275477 650_2 $$2MeSH$$aMiddle Aged
000275477 650_2 $$2MeSH$$aAged
000275477 650_2 $$2MeSH$$aBreast Neoplasms: pathology
000275477 650_2 $$2MeSH$$aOsteoprotegerin
000275477 650_2 $$2MeSH$$aProspective Studies
000275477 650_2 $$2MeSH$$aLigands
000275477 650_2 $$2MeSH$$aTNF-Related Apoptosis-Inducing Ligand
000275477 650_2 $$2MeSH$$aTumor Necrosis Factor-alpha
000275477 650_2 $$2MeSH$$aApoptosis
000275477 650_2 $$2MeSH$$aBiomarkers
000275477 650_2 $$2MeSH$$aHormones
000275477 7001_ $$0P:(DE-He78)bce1fdec5ce564e2666156d96aeabec9$$aJung, Audrey Ying-Chee$$b1$$eFirst author$$udkfz
000275477 7001_ $$0P:(DE-He78)79ab945544e5bc017a2317b6146ed3aa$$aJohnson, Theron S$$b2$$udkfz
000275477 7001_ $$0P:(DE-He78)6b04712f3afe72044d496a25505cb1ea$$aBehrens, Sabine$$b3$$udkfz
000275477 7001_ $$aObi, Nadia$$b4
000275477 7001_ $$aBecher, Heiko$$b5
000275477 7001_ $$0P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aChang-Claude, Jenny$$b6$$udkfz
000275477 7001_ $$0P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aTurzanski-Fortner, Renée$$b7$$eLast author$$udkfz
000275477 773__ $$0PERI:(DE-600)2041618-0$$a10.1186/s13058-023-01625-4$$gVol. 25, no. 1, p. 42$$n1$$p42$$tBreast cancer research$$v25$$x1465-5411$$y2023
000275477 909CO $$ooai:inrepo02.dkfz.de:275477$$pVDB
000275477 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2d4cac0f4bf270325b98fe07036dc6c6$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000275477 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bce1fdec5ce564e2666156d96aeabec9$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000275477 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)79ab945544e5bc017a2317b6146ed3aa$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000275477 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6b04712f3afe72044d496a25505cb1ea$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000275477 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000275477 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000275477 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000275477 9141_ $$y2023
000275477 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-03-30
000275477 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-03-30
000275477 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-03-30
000275477 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-03-30
000275477 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBREAST CANCER RES : 2022$$d2023-08-26
000275477 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-26
000275477 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-26
000275477 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-26
000275477 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-05-02T09:05:15Z
000275477 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-05-02T09:05:15Z
000275477 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-05-02T09:05:15Z
000275477 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-26
000275477 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-26
000275477 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-26
000275477 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBREAST CANCER RES : 2022$$d2023-08-26
000275477 9202_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000275477 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000275477 9200_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000275477 980__ $$ajournal
000275477 980__ $$aVDB
000275477 980__ $$aI:(DE-He78)C020-20160331
000275477 980__ $$aUNRESTRICTED